HCAT

#3818
Health Catalyst, Inc - Common stock
1.7 2 USD
+0.05%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.70
1.75
Intervallo Annuale
0.96
3.62
Variazione giornaliera
+4.88%
Variazione Mensile
-20.00%
Variazione di 6 mesi
+8.18%
Variazione Annuale
-46.91%
Chiusura Precedente
1.6 4
Open
1.7 3
Minimo
1.7 0
Massimo
1.7 5
Volume
213
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Health Catalyst, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Health Catalyst, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Health Catalyst, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Health Catalyst, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Health Catalyst, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Health Catalyst, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Health Catalyst, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Health Catalyst, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Health Catalyst, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Health Catalyst, Inc. current report, Q1 FY2026
8-K

Health Catalyst, Inc. current report, Q3 FY2025

Full document

Health Catalyst, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated July 9, 2025, details the results of Health Catalyst, Inc.'s Annual Meeting of Stockholders. The filing covers the voting outcomes for four specific proposals presented to shareholders.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.

Material Changes and Voting Results

Stockholders voted on four proposals with the following outcomes:

  • Proposal 1 (Election of Directors): Two Class III directors were elected for three-year terms.
    • Duncan Gallagher: 37,136,561 votes For; 9,402,545 votes Withheld.
    • Dr. Jill Hoggard Green: 45,320,332 votes For; 1,218,774 votes Withheld.
  • Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2025.
    • Results: 53,070,196 votes For; 26,656 votes Against; 28,989 Abstentions.
  • Proposal 3 (Executive Compensation): The advisory vote to approve Named Executive Officer compensation was approved.
    • Results: 45,000,705 votes For; 768,325 votes Against; 770,076 Abstentions.
  • Proposal 4 (Board Declassification): The advisory vote to approve the Board initiating action to declassify the Board of Directors was approved.
    • Results: 46,174,256 votes For; 345,811 votes Against; 19,039 Abstentions.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies. The document is limited to reporting the historical voting results of the Annual Meeting.

Key Facts for Investor Verification

  • Voting Participation: Of 69,601,233 shares entitled to vote, 53,125,841 shares were present or represented by proxy.
  • Board Structure Change: Shareholders approved the initiation of action to declassify the Board of Directors, which may alter the election cycle for future directors.
  • Auditor Continuity: The appointment of Ernst & Young LLP as the independent registered public accounting firm was ratified.
  • Director Support: Dr. Jill Hoggard Green received significantly higher support (approx. 79% For) compared to Duncan Gallagher (approx. 64% For) in the director election.

Notizie